Updated safety analysis

 

Ongoing safety evaluations from ocrelizumab clinical trials and associated open-label extension periods, as well as selected post-marketing safety data.

Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis
Hauser SL, Kappos L, Montalban X, et al. Presented at MSVirtual2020, 8th Joint American Committee for Treatment and Research in Multiple Sclerosis Meeting (ACTRIMS)-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Meeting; 11-13 September 2020.
Download PDF (765kb)

COVID-19 in ocrelizumab-treated people with multiple sclerosis

Hughes R, Whitley L, Fitovski K, et al. Mult Scler Relat Disord 2021;49;102725

Go to paper*


*By clicking on the above link you will be redirected to a third-pary website. Roche accepts no responsibility for the content of other websites

Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study

Bar-Or A, Calkwood JC, Chognot C, et al. Neurology. 2020;95:e1999-e2008.

Go to paper*


*By clicking on the above link you will be redirected to a third-pary website. Roche accepts no responsibility for the content of other websites

Cases Reported as Progressive Multifocal Leukoencephalopathy in Ocrelizumab-Treated Patients With Multiple Sclerosis
Clifford DB, Gass A, Richert N, et al. Presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Stockholm, Sweden; 11-13 September 2019.
Download PDF (1154kb)
Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis
Stokmaier D, Winthrop K, Chognot C, et al. Presented at the European Academy of Neurology (EAN) in Lisbon, Portugal; 16-19 June 2018.
Download PDF (205kb)

COVID-19 in Persons with Multiple Sclerosis Treated With Ocrelizumab - A Pharmacovigilance Case Series

Hughes R, Pedotti R, Koendgen H. Mult Scler Relat Disord. 2020;42:102192.

Go to paper*


*By clicking on the above link you will be redirected to a third-pary website. Roche accepts no responsibility for the content of other websites

Prescribing information

Indications vary in different countries. The local prescribing information from your country is the primary source of information on the known and potential risks associated with ocrelizumab.